Columbus Macro LLC Makes New Investment in Humana Inc. (NYSE:HUM)

Columbus Macro LLC bought a new stake in Humana Inc. (NYSE:HUM) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 877 shares of the insurance provider’s stock, valued at approximately $223,000.

Several other large investors have also modified their holdings of the stock. Creative Financial Designs Inc. ADV lifted its holdings in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after buying an additional 61 shares during the last quarter. Atwood & Palmer Inc. acquired a new stake in shares of Humana during the third quarter worth $29,000. Ashton Thomas Securities LLC bought a new position in shares of Humana in the 3rd quarter worth about $31,000. Your Advocates Ltd. LLP boosted its holdings in shares of Humana by 81.8% in the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. Finally, LRI Investments LLC grew its position in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after buying an additional 143 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HUM. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and lifted their target price for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Royal Bank of Canada dropped their target price on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. KeyCorp assumed coverage on shares of Humana in a report on Friday, October 11th. They set a “sector weight” rating for the company. TD Cowen increased their price objective on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Finally, Wells Fargo & Company decreased their target price on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $297.68.

Humana Price Performance

NYSE HUM opened at $295.68 on Wednesday. Humana Inc. has a 1 year low of $213.31 and a 1 year high of $406.46. The business’s fifty day moving average is $275.13 and its two-hundred day moving average is $300.37. The stock has a market capitalization of $35.60 billion, a P/E ratio of 26.19, a P/E/G ratio of 2.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.76 and a current ratio of 1.76.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.29% of the stock is currently owned by company insiders.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.